Table 1.
Genetic alterations in acinic cell carcinoma associated with molecular therapeutic agents.
| Case | Gene | Mutation | OnkoKB Level | Therapeutic Agent |
|---|---|---|---|---|
|
| ||||
| ACI_01 | NF1 | A1873fs | 4 | MEK1/2 inhibitor |
|
| ||||
| ACI_06 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_12 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
| CHEK2 | Y445* | 3B | PARP inhibitor | |
| PTEN | H93L | 4 | PI3K inhibitor | |
|
| ||||
| ACI_16 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_17 | CDKN2A | R80* | 4 | CDK4/6 inhibitor |
| CDKN2B | Structural variant | |||
| NF1 | Deletion | 4 | MEK1/2 inhibitor | |
|
| ||||
| ACI_21 | ATM | X1313_splice | 3B | PARP inhibitor |
|
| ||||
| ACI_22 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_23 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
| ATM | E2245* | 3B | PARP inhibitor | |
|
| ||||
| ACI_26 | PIK3CA | C420R | 3B | PI3K inhibitor |
| CDKN2A | Structural variant | |||
|
| ||||
| ACI_28 | CDKN2A2B | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_29 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_30 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_31 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_33 | CDKN2A/B | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_34 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_37 | ATM | Deletion | 3B | PARP inhibitor |
| CHEK1 | Deletion | 3B | PARP inhibitor | |
| CDKN2A | Deletion | 4 | CDK4/6 inhibitor | |
|
| ||||
| ACI 38 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
| PTEN | Deletion | 4 | PI3K inhibitor | |
|
| ||||
| ACI_39 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_42 | CDKN2A | Deletion | 4 | CDK4/6 inhibitor |
|
| ||||
| ACI_55 | CDKN2A | Structural variant | 4 | CDK4/6 inhibitor |
| PTEN | E242* | 4 | PI3K inhibitor | |